Probiotic breath freshener
- High dose of the patented oral probiotic strain Streptococcus salivarius K12
- Fights bacteria that cause bad breath
- Promotes a healthy oral microbiome, which acts as a first line of defence against infections
- Naturally sweetened with a fresh minty taste
$42.44 — or subscribe and save 20%
Out of stock
Halitosis, or bad breath, can be caused by a number of factors. It may indicate a local exposure to malodorous foods, an infection or a deeper more systemic concern. The odour itself relates to volatile compounds that have a high sulfur content and are produced by gram negative bacteria on the tongue, or between and around teeth. Halitosis can be transient (such as from sulfuric foods, tobacco products, or dry mouth) or it can persist. Persistent halitosis can indicate a systemic or local infection, post nasal drip, GERD, kidney disease, or even liver failure, though systemic diseases only account for 10% of these cases. Cleaning the tongue, by brushing or with mouthwashes, can remove some of the offensive compounds (food remnants, dead cells etc.) that the bacteria feed on, clear away bacteria themselves, or mask the odour for a period of time. But treatment of the underlying cause is ultimately best practice. One of the most effective treatments is to ensure that the oral microbiota is healthy. Breath Biotics with BLIS K12 contains a patented strain of the probiotic Streptococcus salivarius K12, to ensure a healthy oral microflora. By increasing the good bacteria present in the mouth you can reduce bacteria that cause bad breath, and strengthen your first line of defense against infections.
AOR’s Breath Biotics provides one billion CFU (colony forming units) of the well-researched, patented strain of healthy bacteria Streptococcus salivarius K12, in a delicious, mint flavoured lozenge for improved oral health. Breath biotics with BLIS K12 is a perfect product for combating any form of bad breath, and can be used in place of chewing gum or mints to freshen breath while addressing the heart of the problem and promoting oral health.
Breath Biotics is Streptococcus salivarius K12, an oral probiotic which helps reduce halitosis (bad breath), following antimicrobial rinsing and promotes oral health. Breath Biotics can also help reduce the incidence of sore throat caused by pathogenic Streptococcus pyogenes.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, sesame seeds, sulphites, mustard, eggs or shellfish.
For general oral health, take one to two lozenges per day. For prevention of sore throat due to infection in adults, take one to two lozenges per day for 90 days. To reduce halitosis, following use of an antimicrobial mouthwash (such as chlorhexidine or cetylpyridinium chloride), take up to four lozenges a day for a minimum of 14 days. This lozenge is not to be chewed or directly swallowed; it must be slowly dissolved in the mouth. If you are on antibiotics, take at least 24 hours following last dose.
For prevention of sore throat due to infection in children under 12 years of age, take one lozenge per day for 90 days; children 12 years and older, take one to two lozenges per day for 90 days. To reduce halitosis, following use of an antimicrobial mouthwash (such as chlorhexidine or cetylpyridinium chloride), children older than nine years, take up to four lozenges a day for a minimum of 14 days; children nine years and younger, take one lozenge a day for a minimum of seven days. This lozenge is not to be chewed or directly swallowed; it must be slowly dissolved in the mouth. Children under six years of age should be supervised (to not swallow). If you are on antibiotics, take at least 24 hours following last dose.
Consult a health care practitioner prior to use if you have fever, vomiting, bloody diarrhea, or severe abdominal pain. Do not use if you have an immune compromised condition (e.g. AIDS, lymphoma, undergoing long-term corticosteroid treatment), are taking aminoglycoside antibiotics (e.g. kanamycin, streptomycin), or have a dairy allergy. If symptoms of ear, nose or throat infections (e.g. fever, sore throat) occur, or if symptoms of digestive upset (e.g. diarrhea) occur, worsen or persist beyond three days, discontinue use and consult a health care practitioner. Do not use if you have a corn allergy.
- Bad breath
- Oral health
- Sore throat
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
*BLIS™ and BLIS K12™: is a registered trademark of Blis Technologies Limited and the subject of USA patent no. 6773912
Non-medicinal Ingredients: Isomalt, sodium stearyl fumarate, maltodextrin, monk fruit extract, starch, hyprolose, trehalose, lacitol, natural flavour (wintergreen, peppermint).
In a small preliminary study, 23 subjects with halitosis underwent a three-day regimen of mouthwash (chlorhexidine) use, followed by the use of either S. salivarius K12 lozenges or a placebo lozenge. After 1 week of treatment, 85% of the group treated with S. salivarius K12 had a reduction in volatile sulphur compound (VSC) levels >100pb compared to 30% of the placebo group.
In a study of 208 children with halitosis (organoleptic test (OLT) score of 2 or more), subjects were randomized to one of four groups: A. regular tooth brushing and flossing; B. brushing, flossing and tongue scraping; C. brushing, flossing, tongue scraping, and chlorhexidine mouthwash use; D. brushing, flossing, tongue scraping, chlorhexidine mouthwash use, and Streptococcus salivarius K12 probiotic. Moderate to major improvements were seen in OLT scores in a significant number of subjects in Group D. Improvements in groups A and B were neither significant or stable from 1 week to 3 months.
Jamali Z, Aminabadi NA, Samiei M, et al. (2016). Impact of chlorhexidine pretreatment followed by probiotic Streptococcus salivarius strain K12 on halitosis in children: a randomized controlled clinical trial. Oral Health Prev Dent. 14(4): 305-13
Decreases incidence of pharyngeal infections
A study was conducted on children aged 3 to 12 years from multiple daycare centers. Of the 82 participants, 65 were with and 17 were without a history of three or more recurrent episodes of pharyngitis and/or tonsillitis in the previous year. Forty-five of the 65 children with recurrent infections were treated with BLIS K12 (group A), whereas all remaining children were given no treatment and served as control groups (group B: recurrent infections, no treatment, and group C: non-recurrent infections, no treatment).
After the 90-day treatment period, treatment group A had a significantly decreased incidence of oral and pharyngeal infections, from 152 episodes in the previous year compared to only 3 episodes during the 90-day treatment period. By comparison, control groups B and C had an increased number of infectious episodes compared to the previous year. During the 6-month follow-up period after the 90 days of treatment, there was about a 65% reduction in incidence of pharyngeal and ear infections.
Di Pierro F, Donato G, Fomia F, et al. (2012). Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 5: 991-7
In a study of 130 children with recurrent pharyngo-tonsillar infections (three or more episodes of infection over a 6-month period, or four or more episodes over a 12-month period), 76 children were treated with the K12 probiotic daily for 90 days, and 54 children who made up the control group did not receive treatment. All children were followed for 12 months. Those given the probiotic had significantly less infections than in the period before treatment, and a greater reduction than the control group.
Gregori G, Righi O, Risso P, et al. (2016). Reduction of group A beta-hemolytic streptococcus pharygo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 12: 87-92
In a multicenter clinical trial, 222 children aged 3 years were randomized to receive either a slow-dissolving BLIS K12 tablet containing 1 billion CFUs daily or no treatment for 6 months. Children were monitored for an additional 3 months. Researchers evaluated the incidences of streptococcal pharyngo-tonsillitis and acute otitis media (ear infection) in both groups. For children treated with K12, the incidence of these conditions was 16% and 44%, respectively, compared to 48% and 80% in the control group. The researchers concluded that children given BLIS K12 daily have significant reductions in episodes of streptococcal pharyngitis and acute otitis media.
Di Pierro F, Colombo M, Giuliani MG, et al. (2016). Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 20(21): 4601-6
Customers also bought
You may also like…
Superior absorption & gastric tolerability
- Provides nutrients that prevent and treat iron deficiency anemia
- Contains a highly absorbable form of iron
- Includes nutrients and vitamins that aid in the body’s usage of iron
- Non-constipating formula that is easier on the stomach than other iron formulas